CA3092907A1 - Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor - Google Patents
Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor Download PDFInfo
- Publication number
- CA3092907A1 CA3092907A1 CA3092907A CA3092907A CA3092907A1 CA 3092907 A1 CA3092907 A1 CA 3092907A1 CA 3092907 A CA3092907 A CA 3092907A CA 3092907 A CA3092907 A CA 3092907A CA 3092907 A1 CA3092907 A1 CA 3092907A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- adenovirus
- cdk4
- combination
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| EPEP18000210.7 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092907A1 true CA3092907A1 (en) | 2019-09-12 |
Family
ID=61569019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092907A Pending CA3092907A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021517119A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210031852A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533620B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019232768B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092907A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3762004T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965632T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3762004T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE064471T2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007873VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019170283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021044061A1 (en) * | 2019-09-05 | 2021-03-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) * | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| US9271988B2 (en) * | 2011-07-01 | 2016-03-01 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
-
2019
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/da active
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/ko not_active Ceased
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/ja active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620B/zh active Active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 KR KR1020267017074A patent/KR20260089640A/ko active Pending
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en not_active Ceased
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/hu unknown
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 ES ES19710999T patent/ES2965632T3/es active Active
- 2019-03-05 AU AU2019232768A patent/AU2019232768B2/en active Active
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/fi active
-
2024
- 2024-10-23 JP JP2024186627A patent/JP2025013934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019170283A8 (en) | 2019-11-07 |
| CN112533620A (zh) | 2021-03-19 |
| AU2019232768B2 (en) | 2025-12-18 |
| HUE064471T2 (hu) | 2024-03-28 |
| EP3762004B1 (en) | 2023-09-13 |
| EP3762004A1 (en) | 2021-01-13 |
| DK3762004T3 (da) | 2023-11-27 |
| AU2019232768A1 (en) | 2020-09-03 |
| CN112533620B (zh) | 2025-03-28 |
| US20210038661A1 (en) | 2021-02-11 |
| SG11202007873VA (en) | 2020-09-29 |
| ES2965632T3 (es) | 2024-04-16 |
| KR20260089640A (ko) | 2026-06-15 |
| RU2020132466A (ru) | 2022-04-05 |
| JP2025013934A (ja) | 2025-01-28 |
| KR20210031852A (ko) | 2021-03-23 |
| RU2020132466A3 (cg-RX-API-DMAC7.html) | 2022-04-05 |
| WO2019170283A1 (en) | 2019-09-12 |
| FI3762004T3 (fi) | 2023-12-11 |
| JP2021517119A (ja) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity | |
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| Alonso et al. | ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo | |
| JP2007511212A (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| Libertini et al. | Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl 922-947 | |
| Sagara et al. | Development of new oncolytic virotherapy targeting breast cancer using coxsackievirus B3 | |
| Dias et al. | Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1 | |
| JP4982680B2 (ja) | デコリン遺伝子を含む薬剤学的抗腫瘍組成物 | |
| Mato-Berciano et al. | A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel | |
| WO2012022496A2 (en) | Method for killing tumor stem cells | |
| Tookman et al. | RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer | |
| Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
| Mullen et al. | Oncolysis by viral replication and inhibition of angiogenesis by a replication‐conditional herpes simplex virus that expresses mouse endostatin | |
| Aguirre-Hernández et al. | Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy | |
| Yoo et al. | Vaccinia virus‐mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP | |
| JP7834342B2 (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| Wang et al. | HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| CN102250904B (zh) | 一种预防和/或治疗黑色素瘤的药物 | |
| Srivastava et al. | Mode of cell death associated with adenovirus-mediated suicide gene therapy in HNSCC tumor model | |
| Guo et al. | Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate | |
| Zhang et al. | Prox1 Suppresses Proliferation and Drug Resistance of Retinoblastoma Cells via Targeting Notch1 | |
| Aguirre | The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy | |
| Maya-Pineda | Sensitization of prostate cancer cells to cytotoxic drugs induced by the small adenoviral E1A12S protein through multiple cell death/signalling pathways.. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240228 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240711 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250117 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250123 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250123 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250123 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250224 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250224 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250724 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20251020 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S) Effective date: 20260527 |